Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes?

Cigna (CI) is a Top Dividend Stock Right Now: Should You Buy?

Cigna is growing rapidly and earnings per share have increased 13% annually over the past 4 years. The long-term outlook is also positive: Cigna is targeting annual EPS growth between 10% and 13%. About 20% of cash flow from operations is spent on dividends and about 70% on share repurchases and strategic mergers and acquisitions, further increasing shareholder value.

Cigna: Many Reasons To Invest

DexCom

Elevance Health Inc

Exact Sciences

Humana

Eli Lilly

UnitedHealth Group

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public offering market that boomed and fizzled, and D.C.

These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.

Alibaba

Capital One

Coherent Corp

JD.com

Liberty Latin America

New York Community Bancorp

Sibanye Stillwater

Signet Jewelers

Zoom Video

Michael Burry invested a lot of money into the stock market last quarter, according to 13F filings. The "Big Short" investor who has held a bearish tilt towards stocks initiated 17 new positions last quarter.

These are the top 10 stocks held by 'Big Short' investor Michael Burry

CVS Health

The U.S. Federal Trade Commission said it had sought information from two privately held companies that negotiate drug rebates on behalf of pharmacy benefit managers (PBMs) as part of its probe into how PBMs affect pricing of prescription drugs.

US FTC expands probe into pharmacy benefit managers

Amgen

Bristol-Myers

Centene

Gilead Sciences

Labcorp Holdings Inc

Organon & Co

Pfizer

Viatris

The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.

9 Cheap Healthcare Stocks to Consider

Cigna (CI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Cigna Group (CI) Is a Trending Stock: Facts to Know Before Betting on It

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has upgraded most of the Long-Term Issuer Credit Ratings (Long-Term ICRs) to “a+” (Excellent) from “a” (Excellent) and affirmed the Financial Strength Rating (FSR) of A (Excellent) of the key U.S. life/health subsidiaries, health maintenance organizations and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) [NYSE: CI]. The outlook of the Long-Term ICRs has been revised to stable from positive while the outlook.

AM Best Upgrades Issuer Credit Ratings of The Cigna Group and Most of Its Subsidiaries

Novo Nordisk

Sanofi

A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.

Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate

Accenture Plc

Archer-Daniels-Midland Company

Automatic Data Processing

Ball Corp

Franklin Resources

British American Tobacco

Boston Properties

Carlisle Companies

Coterra Energy

Chevron

EOG Resources

Enterprise Products Partners

Johnson & Johnson

Lennar

Lowe's

MPLX

Merck

Microsoft

Anglo American PLC

NIKE

NRG Energy

Rio Tinto plc Sponsored

Truist Financial

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying and are offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.

5 Conservative And Cheap Dividend Stocks To Invest In - May 2023

LOS ANGELES--(BUSINESS WIRE)--AHF Blasts ‘Parasitic' PBM Owner Cigna on $1.3B Q1 Profits.

AHF Blasts ‘Parasitic' PBM Owner Cigna on $1.3B Q1 Profits

Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.

Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View

The Cigna Group (NYSE:CI ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Ralph Giacobbe - SVP & Head of IR David Cordani - Chairman & CEO Brian Evanko - EVP & CFO Conference Call Participants Lisa Gill - J.P. Morgan Steven Valiquette - Barclays Bank Nathan Rich - Goldman Sachs Albert Rice - Crédit Suisse Justin Lake - Wolfe Research Erin Wright - Morgan Stanley Kevin Fischbeck - Bank of America Securities Gary Taylor - TD Cowen Stephen Baxter - Wells Fargo Securities Joshua Raskin - Nephron Research Scott Fidel - Stephens Inc. Kevin Caliendo - UBS Investment Bank Operator Ladies and gentlemen, thank you for standing by for Cigna's First Quarter 2023 Results Review.

Cigna Corporation (CI) Q1 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Cigna (CI) Q1 Earnings

Cigna (CI) came out with quarterly earnings of $5.41 per share, beating the Zacks Consensus Estimate of $5.23 per share. This compares to earnings of $6.01 per share a year ago.

Cigna (CI) Surpasses Q1 Earnings and Revenue Estimates

The Cigna Group reported $1.3 billion in first quarter profits, partly thanks to 1.5 million new enrollees in its health plans including Obamacare.

Cigna Profits Eclipse $1.2 Billion While Adding 1.5 Million New Health Plan Members

Shares of Cigna Group CI gained 0.5% in premarket trading Friday, to bounce off the previous session's 11-month closing low, after the health insurer beat profit and revenue expectations and raised its full-year outlook, even as total customer relationships fell. Net income rose to $1.27 billion, or $4.24 a share, from $1.20 billion, or $3.73 a share, in the year-ago period.

Cigna stock bounces of 11-month low after profit and revenue beat expectations, outlook raised

Total revenues in the first quarter were $46.5 billion    Shareholders' net income for the first quarter was $1.3 billion, or $4.24 per share   Adjusted income from operations1 for the first quarter was $1.6 billion, or $5.41 per share   2023 outlook2 for adjusted income from operations1,2 increased to at least $24.70 per share2 BLOOMFIELD, Conn. , May 5, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today reported strong first quarter 2023 results reflecting growth and focused execution across our diversified portfolio of businesses.

The Cigna Group Reports Strong First Quarter 2023 Results, Raises 2023 Outlook

This is Why Cigna (CI) is a Great Dividend Stock

The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.

Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?

Domino's Pizza

MarketAxess Holdings

Monolithic Power Systems

MSCI

Charles Schwab

I present my top 15 high-growth dividend stocks to consider during the month of May. The watchlist posted a gain of 0.41% in April, trailing both VIG and SPY.

My Top 15 High-Growth Dividend Stocks For May 2023

News for Cigna Stock (CI)